A 52 Week Open Label Trial of Memantine for Frontotemporal Lobar Degeneration

• Status: Completed
• Trial end date: 2006-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a 52-week, multicenter, open label trial of memantine (Namenda) for frontotemporal lobar degeneration (FTLD). The goal is to determine the safety and tolerability of this FDA-approved medication for Alzheimer's Disease in patients with FTLD. Secondary outcome measures include cognitive batteries, rating scales for activities of daily living and neuropsychiatric symptoms. All patients receive the FDA-approved dose of this medication for Alzheimer's disease.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of California, San Francisco
• Collaborator: Forest Laboratories
• Treatments: Memantine

Criteria

Inclusion Criteria:

• Neary et al. Criteria for Frontotemporal Lobar Degeneration

• Age 40 -80

• CDR < 3 or MMSE > 15

• English Speaking

• Study Partner

Exclusion Criteria:

• Concurrent use of antipsychotic drugs or acetylcholinesterase inhibitors